Navigation Links
Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
Date:1/7/2008

BOCA RATON, Fla., Jan. 7 /PRNewswire/ -- Breckenridge announced today that it has entered into an agreement with Helm AG to develop and manufacture a generic tablet ANDA product. Breckenridge expects to file an ANDA with the FDA in January 2008. Upon approval by the FDA, Helm AG will supply and Breckenridge will market and distribute the product on an exclusive basis.

Under terms of the agreement, Breckenridge will submit an ANDA to the U.S. Food and Drug Administration (FDA) for the product which as been developed by Helm AG. The product currently shows U.S. sales of approximately $800 million.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand(TM) and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, more than 150 sku's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. http://www.bpirx.com

About Helm AG:

Helm AG is an international chemical and pharmaceutical organization and a multifunctional marketing group which operates as a link between producers and industrial end users.

With branch offices and participations in 32 countries HELM provides a wide range of services including marketing, distribution, production, logistics, generic development and registration. http://www.helmag.com

For Further Information, please contact:

Breckenridge Pharmaceutical Helm New York, Inc.

Larry Lapila, Vice President Boy Ehlers, Vice President

Business Development Pharmaceutical Division

TEL: 860-828-8140 TEL: 732-981-1160

FAX: 860-828-8142 FAX: 732-981-0965

e-Mail: llapila@bpirx.com behlers@helmnewyork.com


'/>"/>
SOURCE Breckenridge Pharmaceutical
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Patient-Centric Healthcare Study Reveals Key Insights for Pharmaceutical Marketers
2. KV Pharmaceutical Company Announces NYSE Listing Extension
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
4. Pharmaceutical Sales: Best Practices for Pharmaceutical Sales Success
5. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
6. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
7. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
8. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
9. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
10. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
11. Par Pharmaceutical Reports Third-Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... ... 17, 2017 , ... The Alliance Healthcare Foundation (AHF) announced ... positively impact the health and wellness of our community in San Diego and ... to seriously consider releasing our assets beyond our 5% targeted distribution each year ...
(Date:2/17/2017)... VA (PRWEB) , ... February 17, 2017 , ... ... the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017  Newly published research from the CVS ... the role a private retailer can play in restricting ... published online today in the American Journal of ... remove tobacco from all CVS Pharmacy stores reduced the ... an even greater impact on those who bought cigarettes ...
(Date:2/16/2017)... -- Summary Provides understanding and access to the ... healthcare companies. ... The Global Allergy Partnering Terms and Agreements since 2010 report ... by the world,s leading healthcare companies. - Trends ... Deals listed by company A-Z, industry sector, stage of development, technology ...
(Date:2/16/2017)... , Feb 16, 2017 Research and Markets ... Diagnostics Market Analysis & Trends - Function, Application, Cancer Type, Technology ... ... Cancer Diagnostics Market is poised to grow at a CAGR of ... by 2025. Some of the prominent trends ...
Breaking Medicine Technology: